Dana Washburn

Dana Washburn joined Rhythm Pharmaceuticals in September 2022 as Senior Vice President of Clinical Development. Dana brings more than 20 years of experience in biopharmaceuticals and medical devices as a physician executive. Most recently, he was Executive Director and Global Medicine Leader at Alexion Pharmaceuticals, which became AstraZeneca Rare Disease following its July 2021 acquisition. Prior to that, Dana was Chief Medical Officer at Lyra Therapeutics, Corporate Vice President and Head of Global Medical Services for Parexel International, and CMO of Lantheus Medical Imaging. Earlier in his career, he was a cardiologist at the Framingham Heart Center, and he also served as Assistant Director of the Cardiovascular Hemodynamic and Imaging Laboratory at Tufts Medical Center. Dana holds a medical degree from the University of Massachusetts.